Trafficking of endogenous smooth muscle cell cholesterol a role for serum amyloid a and interleukin-1β

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 11, 2012, Pages 2741-2750

  Pessolano Jr , Lawrence G ^a   Sullivan, Christopher P ^a   Seidl, Stephanie E ^a   Rich, Celeste B ^a   Liscum, Laura ^b   Stone, Phillip J ^a   Sipe, Jean D ^a   Schreiber, Barbara M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol trafficking; Interleukin 1 ; Serum amyloid A; Smooth muscle cells

Indexed keywords

CARBON 14; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL OXIDASE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; OLEIC ACID; SECRETORY PHOSPHOLIPASE A2; SERUM AMYLOID A; SPHINGOMYELIN PHOSPHODIESTERASE; TRITIUM; AUTACOID; ENZYME INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERMEDIATE DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; AORTA MEDIA; ARTICLE; ATHEROSCLEROSIS; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENDOSOME; ENZYME ACTIVATION; ENZYME ACTIVITY; LYSOSOME; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; VASCULITIS; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; SPRAGUE DAWLEY RAT; TIME; TRANSPORT AT THE CELLULAR LEVEL; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANIMALS, NEWBORN; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL ESTERS; CHOLESTEROL OXIDASE; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LIPOPROTEINS, IDL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OLEIC ACID; PHOSPHOLIPASES A2, SECRETORY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, INTERLEUKIN-1; SERUM AMYLOID A PROTEIN; SPHINGOMYELIN PHOSPHODIESTERASE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871913756     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300243     Document Type: Article

References (57)

1. Mesmin B, Maxfeld FR. Intracellular sterol dynamics. Biochim Biophys Acta. 2009;1791:636-645.
2. Liscum L, Munn NJ. Intracellular cholesterol transport. Biochim Biophys Acta. 1999;1438:19-37.
3. Fielding CJ, Fielding PE. Cholesterol and caveolae: structural and functional relationships. Biochim Biophys Acta. 2000;1529:210-222.
4. Chang TY, Chang CC, Ohgami N, Yamauchi Y. Cholesterol sensing, traf-fcking, and esterifcation. Annu Rev Cell Dev Biol. 2006;22:129-157.
5. Brown MS, Goldstein JL. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J Lipid Res. 2009;50 Suppl:S15-S27.
6. Maxfeld FR, Menon AK. Intracellular sterol transport and distribution. Curr Opin Cell Biol. 2006;18:379-385.
7. Slotte J P, Bierman EL. Depletion of plasma-membrane sphingomyelin rapidly alters the distribution of cholesterol between plasma membranes and intracellular cholesterol pools in cultured fbroblasts. Biochem J. 1988;250:653-658.
8. Okwu AK, Xu XX, Shiratori Y, Tabas I. Regulation of the threshold for lipoprotein-induced acyl-CoA:cholesterol O-acyltransferase stimulation in macrophages by cellular sphingomyelin content. J Lipid Res. 1994;35:644-655.
9. Schreiber BM. Serum amyloid A; in search of function. Amyloid. 2002;9:276-278.
10. Bujak M, Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz). 2009;57:165-176.
11. Sullivan CP, Seidl SE, Rich CB, Raymondjean M, Schreiber BM. Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism. J Biol Chem. 2010;285:565-575.
12. Nakano T, Ohara O, Teraoka H, Arita H. Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett. 1990;261:171-174.
13. Antonio V, Brouillet A, Janvier B, Monne C, Bereziat G, Andreani M, Raymondjean M. Transcriptional regulation of the rat type IIA phospho-lipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors. Biochem J. 2002;368(Pt 2):415-424.
14. Jaulmes A, Thierry S, Janvier B, Raymondjean M, Maréchal V. Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta. FASEB J. 2006;20:1727-1729.
15. Schreiber BM, Martin BM, Hollander W, Franzblau C. beta-VLDL-induced alterations in growth potentiating activity produced by mono-nuclear phagocytes. Atherosclerosis. 1988;69:69-79.
16. Hsiao H, Stone PJ, Toselli P, Rosenbloom J, Franzblau C, Schreiber BM. The role of the carboxy terminus of tropoelastin in its assembly into the elastic fber. Connect Tissue Res. 1999;40:83-95.
17. Schreiber BM, Jones HV, Toselli P, Franzblau C. Long-term treatment of neonatal aortic smooth muscle cells with beta VLDL induces cholesterol accumulation. Atherosclerosis. 1992;95:201-210.
18. Underwood KW, Andemariam B, McWilliams GL, Liscum L. Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol transport. J Lipid Res. 1996;37:1556-1568.
19. Divchev D, Schieffer B. The secretory phospholipase A2 group IIA: a missing link between infammation, activated renin-angiotensin system, and atherogenesis? Vasc Health Risk Manag. 2008;4:597-604.
20. Jayadev S, Linardic CM, Hannun YA. Identifcation of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha. J Biol Chem. 1994;269:5757-5763.
21. Liscum L. Niemann-Pick type C mutations cause lipid traffc jam. Traffc. 2000;1:218-225.
22. Goldstein JL, Ho YK, Brown MS, Innerarity TL, Mahley RW. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J Biol Chem. 1980;255:1839-1848.
23. Liscum L, Underwood KW. Intracellular cholesterol transport and com-partmentation. J Biol Chem. 1995;270:15443-15446.
24. Street IP, Lin HK, Laliberté F, Ghomashchi F, Wang Z, Perrier H, Tremblay NM, Huang Z, Weech PK, Gelb MH. Slow-and tight-binding inhibitors of the 85-kDa human phospholipase A2. Biochemistry. 1993;32:5935-5940.
25. Skiba PJ, Zha X, Maxfeld FR, Schissel SL, Tabas I. The distal pathway of lipoprotein-induced cholesterol esterifcation, but not sphingomyelin-ase-induced cholesterol esterifcation, is energy-dependent. J Biol Chem. 1996;271:13392-13400.
26. Lister MD, Ruan ZS, Bittman R. Interaction of sphingomyelinase with sphingomyelin analogs modifed at the C-1 and C-3 positions of the sphingosine backbone. Biochim Biophys Acta. 1995;1256:25-30.
27. Orr AW, Hastings NE, Blackman BR, Wamhoff BR. Complex regulation and function of the infammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res. 2010;47:168-180.
28. Chatterjee S. Neutral sphingomyelinase action stimulates signal trans-duction of tumor necrosis factor-alpha in the synthesis of cholesteryl esters in human fbroblasts. J Biol Chem. 1994;269:879-882.
29. Zager RA, Johnson A, Anderson K, Wright S. Cholesterol ester accumulation: an immediate consequence of acute in vivo ischemic renal injury. Kidney Int. 2001;59:1750-1761.
30. Bae JS, Rezaie AR. Thrombin and activated protein C inhibit the expression of secretory group IIA phospholipase A(2) in the TNF-alpha-activated endothelial cells by EPCR and PAR-1 dependent mechanisms. Thromb Res. 2010;125:e9-e15.
31. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med. 1986;314:488-500.
32. Beck S, Lambeau G, Scholz-Pedretti K, Gelb MH, Janssen MJ, Edwards SH, Wilton DC, Pfeilschifter J, Kaszkin M. Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation. J Biol Chem. 2003;278:29799-29812.
33. Thomas G, Bertrand F, Saunier B. The differential regulation of group II(A) and group V low molecular weight phospholipases A(2) in cultured rat astrocytes. J Biol Chem. 2000;275:10876-10886.
34. Oka S, Arita H. Infammatory factors stimulate expression of group II phospholipase A2 in rat cultured astrocytes. Two distinct pathways of the gene expression. J Biol Chem. 1991;266:9956-9960.
35. Vadas P, Pruzanski W, Stefanski E, Ellies LG, Aubin JE, Sos A, Melcher A. Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action. Immunol Lett. 1991;28:187-193.
36. Lindbom J, Ljungman AG, Lindahl M, Tagesson C. Increased gene expression of novel cytosolic and secretory phospholipase A(2) types in human airway epithelial cells induced by tumor necrosis factor-alpha and IFN-gamma. J Interferon Cytokine Res. 2002;22:947-955.
37. Peilot H, Rosengren B, Bondjers G, Hurt-Camejo E. Interferon-gamma induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines. J Biol Chem. 2000;275:22895-22904.
38. Nakano T, Ohara O, Teraoka H, Arita H. Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett. 1990;261:171-174.
39. Slotte JP, Härmälä AS, Jansson C, Pörn MI. Rapid turn-over of plasma membrane sphingomyelin and cholesterol in baby hamster kidney cells after exposure to sphingomyelinase. Biochim Biophys Acta. 1990;1030:251-257.
40. Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem. 1998;46:1377-1384.
41. Cunnane G. Amyloid precursors and amyloidosis in infammatory arthritis. Curr Opin Rheumatol. 2001;13:67-73.
42. Kuwata H, Nakatani Y, Murakami M, Kudo I. Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fbroblasts. J Biol Chem. 1998;273:1733-1740.
43. Kuwata H, Yamamoto S, Miyazaki Y, Shimbara S, Nakatani Y, Suzuki H, Ueda N, Yamamoto S, Murakami M, Kudo I. Studies on a mechanism by which cytosolic phospholipase A2 regulates the expression and function of type IIA secretory phospholipase A2. J Immunol. 2000;165:4024-4031.
44. Murakami M, Kuwata H, Amakasu Y, Shimbara S, Nakatani Y, Atsumi G, Kudo I. Prostaglandin E2 amplifes cytosolic phospholipase A2-and cyclooxygenase-2- dependent delayed prostaglandin E2 generation in mouse osteoblastic cells. Enhancement by secretory phospholipase A2. J Biol Chem. 1997;272:19891-19897.
45. Huwiler A, Staudt G, Kramer RM, Pfeilschifter J. Cross-talk between secretory phospholipase A2 and cytosolic phospholipase A2 in rat renal mesangial cells. Biochim Biophys Acta. 1997;1348:257-272.
46. Balsinde J, Balboa MA, Dennis EA. Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2. Proc Natl Acad Sci USA. 1998;95:7951-7956.
47. Murakami M, Shimbara S, Kambe T, Kuwata H, Winstead MV, Tischfeld JA, Kudo I. The functions of fve distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. J Biol Chem. 1998;273:14411-14423.
48. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-523.
49. Ridker PM. Infammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis. 1999;10 Suppl 1:S9-12.
50. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, Pepine CJ, Sharaf B, Bairey Merz CN, Sopko G, Olson MB, Reis SE. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Circulation. 2004;109:726-732.
51. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
52. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci USA. 1994;91:3186-3190.
53. Yamada T, Kakihara T, Kamishima T, Fukuda T, Kawai T. Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions. Pathol Int. 1996;46:797-800.
54. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest. 1996;26:427-435.
55. Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL, Lusis AJ. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcifcation. Arterioscler Thromb. 1994;14:1480-1497.
56. Kumon Y, Sipe JD, Brinckerhoff CE, Schreiber BM. Regulation of extrahepatic apolipoprotein serum amyloid A (ApoSAA) gene expression by interleukin-1 alpha alone: synthesis and secretion of ApoSAA by cultured aortic smooth muscle cells. Scand J Immunol. 1997;46:284-291.
57. Schreiber BM, Veverbrants M, Fine RE, Blusztajn JK, Salmona M, Patel A, Sipe JD. Apolipoprotein serum amyloid A down-regulates smooth-muscle cell lipid biosynthesis. Biochem J. 1999;344:7-13.